Entera Bio Ltd . (NASDAQ:ENTX), a biotechnology firm specializing in biological products, held its Annual Meeting of Shareholders on July 31, 2024, where several key proposals were voted upon and approved. The Jerusalem-based company, which operates under the laws of the State of Israel, announced the results of the meeting in a Form 8-K filed with the Securities and Exchange Commission on Friday.
The shareholders voted to elect Miranda Toledano and Yonatan Malca to the company's Board of Directors for a three-year term. The vote was overwhelmingly in favor, with Toledano receiving 14,822,807 votes for and Malca securing 14,671,298 votes for their respective appointments.
Additionally, the shareholders ratified and approved a one-time grant of compensation for Miranda Toledano, who serves as the Chief Executive Officer and a Director of the company. The proposal received 14,365,894 votes for, 544,357 against, and 9,344 abstentions.
The revised compensation terms for the company's non-executive directors were also approved with 14,155,236 votes for the proposal. An amendment to the company's 2018 Equity Incentive Plan was ratified, which includes an increase in the number of shares issuable by 1,788,515 shares.
Furthermore, the company's amended and restated compensation policy for directors and officers was ratified and approved, as well as the compensation of the company's named executive officers on an advisory, non-binding basis.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.